MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/101607
NEWS & EVENTS ALLERGAN ACQUIRES SKINMEDICA Allergan (allergan.com) has entered into a de���nitive agreement with SkinMedica (skinmedica.com) to acquire the privately held company���s topical aesthetics skincare business. Under the terms of the agreement, Allergan will pay SkinMedica $350 million up-front���subject to certain adjustments���for the business, which includes a variety of physician-dispensed, non-prescription aesthetic skincare products and prescription products. Allergan will also pay SkinMedica an additional $25 million, contingent upon the acquired products achieving a speci���c level of net sales. The acquisition does not include the SkinMedica Colorescience aesthetic makeup line. ���Allergan is widely recognized for our leadership in the facial aesthetics area,��� said David E.I. Pyott, President and CEO of Allergan. ���The acquisition of SkinMedica will nicely complement our existing facial aesthetics business, which includes products such as BOTOX Cosmetic, JUVEDERM and LATISSE, and will enable us to take a leadership position in the growing ���physician dispensed��� topical aesthetics skincare category.��� Bob Rhatigan, who currently serves as Senior Vice President, Facial Aesthetics, Allergan, will assume the role of Senior Vice President, General Manager and Chief Executive of SkinMedica. Mary Fisher, CEO of SkinMedica, will join Allergan and assist Rhatigan in the acquisition integration to ensure the maximization of revenue building opportunities. BELOTERO BALANCE NOW AVAILABLE NATIONWIDE Practicing physicians in the United States can now purchase BELOTERO BALANCE (belotero.com)���the latest HA ���ller to receive FDA approval. BELOTERO BALANCE was approved by the Food and Drug Administration (fda.gov) in November 2011 as a safe solution for the correction of moderate-tosevere facial wrinkles and folds, such as nasolabial folds and perioral lines. This dermal ���ller joins Merz Aesthetics��� existing portfolio of injectable products, including RADIESSE Volumizing Filler and Asclera (polidocanol) Injection. ���We believe that BELOTERO BALANCE has a unique place in the aesthetic market as a competitive and effective choice that provides physicians with a new option for ensuring meaningful results for patients seeking to treat the appearance of both wrinkles and folds,��� said Dennis 70 JANUARY/FEBRUARY 2013 | MedEsthetics Condon, president of Merz Aesthetics. ���We look forward to the availability of BELOTERO BALANCE as we continue our company���s legacy of providing the ���eld of aesthetic dermatology with unparalleled service and a wide range of safe and effective products.��� ASDS ANNOUNCES NEW OFFICERS The American Society for Dermatologic Surgery (ASDS, asds.net) has announced its newly elected of���cers and board of director members for 2013-2014. Their terms of of���ce began at the Society���s Annual Business Meeting, held during the 2012 ASDS Annual Meeting in Atlanta. George Hruza, MD, of Chester���eld, Missouri was elected vice president. He is a clinical professor of dermatology and otolaryngology at St. Louis University, assistant editor of Dermatologic Surgery and a founding Stegman Circle Member. He will ascend to President-Elect in 2013-14 and to President in 2014-15. Abel Torres, MD, of Loma Linda, California has been elected treasurer. Dr. Torres is a professor and chairman of the Department of Dermatology at Loma Linda University. He has been a member of the ASDS Board of Directors and Audit Committee since 2009. He will serve a threeyear term through 2015. Elected to three-year terms on the Board of Directors are: Marc D. Brown, MD, of Rochester, New York; Cheryl M. Burgess, MD, of Washington, D.C.; and Ken K. Lee, MD, of Portland, Oregon. All three will serve until 2015. ���I look forward to applying my passion, energy and experience to work on your behalf. The ASDS and ASDSA are strong organizations with a dedicated staff and countless physician volunteers,��� said Dr. Hruza. ���The ASDS and ASDSA have leveraged their strengths to punch far above their size on both the national and state levels. The ASDSA must continue to be at the forefront, ���ghting for patient safety through enactment of sensible patient safety regulations at the state level and educating the public about the dangers of the non-physician practice of medicine.��� PLIAGLIS RECEIVES FDA APPROVAL The United States Food and Drug Administration (fda.gov) has approved a supplemental New Drug Application (sNDA) for topical local anesthetic Pliaglis (lidocaine/tetracaine) 7%/7% Cream. Galderma Laboratories (galderma.com), a global pharmaceutical company that specialize in dermatology, will distribute Pliaglis, having licensed worldwide marketing rights from Nuvo Research Inc. Pliaglis Cream uses Nuvo���s proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. It is indicated for use on intact skin in adults to provide local analgesia for super���cial aesthetic procedures, such as dermal ���ller injection, pulsed dye laser therapy, facial